STOCK TITAN

TenX Keane Acquisition Ordinary Share - $TENK STOCK NEWS

Welcome to our dedicated page for TenX Keane Acquisition Ordinary Share news (Ticker: $TENK), a resource for investors and traders seeking the latest updates and insights on TenX Keane Acquisition Ordinary Share stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TenX Keane Acquisition Ordinary Share's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TenX Keane Acquisition Ordinary Share's position in the market.

Rhea-AI Summary
Citius Pharmaceuticals, Inc. resubmitted LYMPHIR™ BLA to the FDA and completed Mino-Lok® Phase 3 trial enrollment. Financially, they reported $20.3 million in cash, with R&D expenses at $2.6 million and a net loss of $9.2 million for Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.07%
Tags
-
Rhea-AI Summary
TenX Keane Acquisition (TENKU, TENK, TENKR) proposes to amend its Amended and Restated Memorandum and Articles of Association to extend the deadline for a business combination up to November 18, 2024, with sponsor contributions if the extension is approved.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
-
Rhea-AI Summary
Citius Pharmaceuticals, Inc. and TenX Keane Acquisition have entered into a definitive agreement for a proposed merger. Citius Pharma will receive $675 million in equity of Citius Oncology and retain approximately 90% majority control. The transaction is expected to close in the first half of 2024. Citius Oncology will focus on developing and commercializing novel targeted oncology therapies, with LYMPHIR as its flagship product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
Rhea-AI Summary
TenX Keane Acquisition extends the date for completing its initial business combination and receives an extension fee of $660,000.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
-
Rhea-AI Summary
TenX Keane Acquisition announces extension of initial business combination date and deposit of $660,000 into trust account.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
TenX Keane Acquisition Ordinary Share

Nasdaq:TENK

TENK Rankings

TENK Stock Data

74.38M
3.27M
26.66%
65.88%
Shell Companies
Financial Services
Link
United States of America
NEW YORK